Skip to main content

NO/cGMP signalling

Most of the effects of the signalling molecule nitric oxide (NO) are mediated by the stimulation of the NO-sensitive guanylyl cyclase (GC) and the subsequent increase in cGMP formation. The enzyme contains a prosthetic heme group which mediates NO stimulation. In addition to the physiological activator NO, NO-sensitisers like the substance YC-1 sensitise the enzyme towards NO and may therefore have important pharmacological implications. Two isoforms of NO-sensitive GC have been identified to date that share regulatory properties but differ in the subcellular localization; the more ubiquitously expressed α1β1 heterodimer and the α2β1 isoform mainly expressed in brain. Knock-out mice in which either one the GC subunits is deleted will provide information about the functional roles of GC and the isoforms.

In intact cells, NO-induced cGMP signalling not only depends on cGMP formation but is also critically determined by the activity of the enzyme responsible for cGMP degradation i.e. phosphodiesterase 5 (PDE5). Recently, direct activation of PDE5 by cGMP was demonstrated which is limiting the cGMP increase and therefore is functioning as a negative feedback. As the cGMP-induced PDE5 activation turned out to be sustained, in the range of hours, it is probably responsible for the NO-induced desensitisation observed within NO/cGMP signalling.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Doris Koesling.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Koesling, D., Mergia, E., Russwurm, M. et al. NO/cGMP signalling. BMC Pharmacol 5, S10 (2005). https://doi.org/10.1186/1471-2210-5-S1-S10

Download citation

Keywords

  • Nitric Oxide
  • Subcellular Localization
  • Phosphodiesterase
  • Regulatory Property
  • Guanylyl Cyclase